The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains

Biomaterials

Volumn 30, Issue 19, 2009, Pages 3318-3323

  Yoshikawa, Tomoaki ^a,b   Sugita, Toshiki ^a,b   Mukai, Yohei ^a,b   Abe, Yasuhiro ^a   Nakagawa, Shinsaku ^b   Kamada, Haruhiko ^a,b   Tsunoda, Shin ichi ^a,b   Tsutsumi, Yasuo ^a,b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Intracellular delivery; Peptide; Phage display; Protein transduction domain (PTD)

Indexed keywords

ANTI-CANCER THERAPEUTICS; ARTIFICIAL PROTEINS; CANCER CELLS; CLINICAL APPLICATIONS; CYTOSTATIC ACTIVITIES; HIGH CONCENTRATIONS; HIGH EFFICIENCIES; IN-VITRO; IN-VIVO; INTRACELLULAR DELIVERY; MACROMOLECULAR DRUGS; MOLECULAR EVOLUTIONS; PEPTIDE THERAPEUTICS; PHAGE DISPLAY; PROTEIN TRANSDUCTION DOMAIN (PTD); SURVIVIN; THERAPEUTIC POTENTIALS; TRANSDUCTION EFFICIENCIES; TUMOR CELLS;

BACTERIOPHAGES; BIOLOGICAL MATERIALS; FUNCTIONAL POLYMERS; LIGANDS; MOLECULAR BIOLOGY; OLIGONUCLEOTIDES;

AMINES;

ANTINEOPLASTIC AGENT; DRUG CARRIER; MT02 PROTEIN; MT03 PROTEIN; PEPTIDE; SHEPHERDIN; SURVIVIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INTERNALIZATION; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SERUM; TUMOR CELL;

AMINO ACID SEQUENCE; BETA-CYCLODEXTRINS; BIOCOMPATIBLE MATERIALS; CELL LINE; CYTOCHALASIN D; CYTOSTATIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDES; PINOCYTOSIS; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC;

EID: 67349189480     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.02.031     Document Type: Article

References (29)

1. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5 (1999) 1032-1038
2. Lien S., and Lowman H.B. Therapeutic peptides. Trends Biotechnol 21 (2003) 556-562
3. Mai J.C., Mi Z., Kim S.H., Ng B., and Robbins P.D. A proapoptotic peptide for the treatment of solid tumors. Cancer Res 61 (2001) 7709-7712
4. Warren P., Li L., Song W., Holle E., Wei Y., Wagner T., et al. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus. Cancer Res 61 (2001) 6783-6787
5. Yan H., Thomas J., Liu T., Raj D., London N., Tandeski T., et al. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. Oncogene 25 (2006) 6968-6974
6. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
7. Derossi D., Joliot A.H., Chassaing G., and Prochiantz A. The third helix of the antennapedia homeodomain translocates through biological membranes. J Biol Chem 269 (1994) 10444-10450
8. Elliott G., and O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88 (1997) 223-233
9. Sugita T., Yoshikawa T., Mukai Y., Yamanada N., Imai S., Nagano K., et al. Comparative study on transduction and toxicity of protein transduction domains. Br J Pharmacol 153 (2008) 1143-1152
10. Yoshikawa T., Sugita T., Mukai Y., Yamanada N., Nagano K., Nabeshi H., et al. Organelle-targeted delivery of biological macromolecules using the protein transduction domain: potential applications for peptide aptamer delivery into the nucleus. J Mol Biol 380 (2008) 777-782
11. Kamada H., Okamoto T., Kawamura M., Shibata H., Abe Y., Ohkawa A., et al. Creation of novel cell-penetrating peptides for intracellular drug delivery using systematic phage display technology originated from Tat transduction domain. Biol Pharm Bull 30 (2007) 218-223
12. Grimmer S., van Deurs B., and Sandvig K. Membrane ruffling and macropinocytosis in A431 cells require cholesterol. J Cell Sci 115 (2002) 2953-2962
13. Liu N.Q., Lossinsky A.S., Popik W., Li X., Gujuluva C., Kriederman B., et al. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol 76 (2002) 6689-6700
14. Sampath P., and Pollard T.D. Effects of cytochalasin, phalloidin, and pH on the elongation of actin filaments. Biochemistry 30 (1991) 1973-1980
15. West M.A., Bretscher M.S., and Watts C. Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells. J Cell Biol 109 (1989) 2731-2739
16. Plescia J., Salz W., Xia F., Pennati M., Zaffaroni N., Daidone M.G., et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7 (2005) 457-468
17. Uchida H., Tanaka T., Sasaki K., Kato K., Dehari H., Ito Y., et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 10 (2004) 162-171
18. Zaffaroni N., Pennati M., and Daidone M.G. Survivin as a target for new anticancer interventions. J Cell Mol Med 9 (2005) 360-372
19. Wadia J.S., Stan R.V., and Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10 (2004) 310-315
20. Kaplan I.M., Wadia J.S., and Dowdy S.F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 102 (2005) 247-253
21. Nakase I., Niwa M., Takeuchi T., Sonomura K., Kawabata N., Koike Y., et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 10 (2004) 1011-1022
22. Fuki I.V., Meyer M.E., and Williams K.J. Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane rafts. Biochem J 3 351 Pt (2000) 607-612
23. Hewlett L.J., Prescott A.R., and Watts C. The coated pit and macropinocytic pathways serve distinct endosome populations. J Cell Biol 124 (1994) 689-703
24. Meier O., Boucke K., Hammer S.V., Keller S., Stidwill R.P., Hemmi S., et al. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J Cell Biol 158 (2002) 1119-1131
25. Murriel C.L., and Dowdy S.F. Influence of protein transduction domains on intracellular delivery of macromolecules. Expert Opin Drug Deliv 3 (2006) 739-746
26. Norbury C.C., Hewlett L.J., Prescott A.R., Shastri N., and Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 3 (1995) 783-791
27. Sugita T., Yoshikawa T., Mukai Y., Yamanada N., Imai S., Nagano K., et al. Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. Biochem Biophys Res Commun 363 (2007) 1027-1032
28. Snyder E.L., Saenz C.C., Denicourt C., Meade B.R., Cui X.S., Kaplan I.M., et al. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res 65 (2005) 10646-10650
29. Tan M., Lan K.H., Yao J., Lu C.H., Sun M., Neal C.L., et al. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 66 (2006) 3764-3772